Amphista Therapeutics: Funding, Investors & Team (Oct 2026)
At Amphista Therapeutics we are developing drugs to bring life-changing medicines to patients. Powered by transformational science we are advancing beyond traditional degrader approaches, addressing limitations associated with the use of a narrow range of protein degrading mechanisms. Amphista Therapeutics is an exciting spin out company founded by Advent Life Sciences and built on groundbreaking science from the laboratory of Professor Alessio Ciulli (University of Dundee), a world leader in the field of targeted protein degradation. Targeted protein degradation (TPD) hijacks the cell’s degradation machinery to modulate abundance of proteins that are responsible for disease progression. Our approach to protein degradation differentiates from traditional TPD technologies and is being developed to treat diseases with high unmet need.
Amphista Therapeutics has raised $53.0M across 2 funding rounds on record, the most recent a Series B announced in Dec 2022.
Amphista Therapeutics Company Profile and Key Stats
Latest funding round on record: Dec 2022.
Amphista Therapeutics Funding Rounds
1 of 2 rounds was announced without a disclosed amount and is excluded from the total.
Amphista Therapeutics raised $53.0M in a Series B announced in Mar 2021.
1.8 years later, a Series B was announced in Dec 2022 with no disclosed amount.
Amphista Therapeutics Founders and Leadership Team
Contact details for the Amphista Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Amphista Therapeutics Funding Compared to Other Biotechnology Startups
Funded Startups Like Amphista Therapeutics in Biotechnology and Motherwell
Companies Similar to Amphista Therapeutics
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
Amphista Therapeutics Funding FAQs
What does Amphista Therapeutics do?
At Amphista Therapeutics we are developing drugs to bring life-changing medicines to patients. Powered by transformational science we are advancing beyond traditional degrader approaches, addressing limitations associated with the use of a narrow range of protein degrading mechanisms. Amphista Therapeutics is an exciting spin out company founded by Advent Life Sciences and built on groundbreaking science from the laboratory of Professor Alessio Ciulli (University of Dundee), a world leader in the field of targeted protein degradation. Targeted protein degradation (TPD) hijacks the cell’s degradation machinery to modulate abundance of proteins that are responsible for disease progression. Our approach to protein degradation differentiates from traditional TPD technologies and is being developed to treat diseases with high unmet need.
How much funding has Amphista Therapeutics raised?
Amphista Therapeutics has raised $53.0M across 2 rounds on record.
When did Amphista Therapeutics last raise funding?
Amphista Therapeutics' most recent funding round on record was announced in Dec 2022. The amount was not disclosed.
Who is the CEO of Amphista Therapeutics?
Nicki Thompson is listed as CEO at Amphista Therapeutics.
Where is Amphista Therapeutics headquartered?
Amphista Therapeutics is based in Motherwell, North Lanarkshire, United Kingdom.
How many employees does Amphista Therapeutics have?
Amphista Therapeutics is in the 51-100 employee band.
About FundedIQ's Amphista Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Amphista Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.